within Pharmacolibrary.Drugs.ATC.S;

model S01AA27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 129 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 750 / 1000000,
    adminCount     = 1,
    Vd             = 0.009300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cefuroxime is a second-generation cephalosporin antibiotic effective against a broad range of Gram-positive and Gram-negative bacteria, commonly used for the treatment of bacterial infections including respiratory tract infections, urinary tract infections, skin infections, and ocular infections. The S01AA27 ATC code denotes its ophthalmic use. Cefuroxime is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult subjects after a single intravenous bolus dose.</p><h4>References</h4><ol><li><p>Thønnings, S, et al., &amp; Frimodt-Møller, N (2020). Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers. <i>Journal of medical microbiology</i> 69(3) 387–395. DOI:<a href=&quot;https://doi.org/10.1099/jmm.0.001138&quot;>10.1099/jmm.0.001138</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31958049/&quot;>https://pubmed.ncbi.nlm.nih.gov/31958049</a></p></li><li><p>Foord, RD (1976). Cefuroxime: human pharmacokinetics. <i>Antimicrobial agents and chemotherapy</i> 9(5) 741–747. DOI:<a href=&quot;https://doi.org/10.1128/AAC.9.5.741&quot;>10.1128/AAC.9.5.741</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/949172/&quot;>https://pubmed.ncbi.nlm.nih.gov/949172</a></p></li><li><p>Gower, PE, &amp; Dash, CH (1977). The pharmacokinetics of cefuroxime after intravenous injection. <i>European journal of clinical pharmacology</i> 12(3) 221–227. DOI:<a href=&quot;https://doi.org/10.1007/BF00609865&quot;>10.1007/BF00609865</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/590309/&quot;>https://pubmed.ncbi.nlm.nih.gov/590309</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01AA27;
